HRP20231131T1 - Protutumorski farmaceutski pripravci za kombiniranu terapiju - Google Patents
Protutumorski farmaceutski pripravci za kombiniranu terapiju Download PDFInfo
- Publication number
- HRP20231131T1 HRP20231131T1 HRP20231131TT HRP20231131T HRP20231131T1 HR P20231131 T1 HRP20231131 T1 HR P20231131T1 HR P20231131T T HRP20231131T T HR P20231131TT HR P20231131 T HRP20231131 T HR P20231131T HR P20231131 T1 HRP20231131 T1 HR P20231131T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- pharmaceutical preparation
- body weight
- pi3kca
- use according
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title claims 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims 5
- 238000002648 combination therapy Methods 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 13
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- 230000037396 body weight Effects 0.000 claims 9
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 208000029742 colonic neoplasm Diseases 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010069755 K-ras gene mutation Diseases 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- JEGHXKRHKHPBJD-UHFFFAOYSA-N 5-(7-methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine Chemical compound CS(=O)(=O)N1CCC2=C1N=C(N1CCOCC1)N=C2C1=CN=C(N)N=C1 JEGHXKRHKHPBJD-UHFFFAOYSA-N 0.000 claims 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 2
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 229960005395 cetuximab Drugs 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 229960002258 fulvestrant Drugs 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 238000011394 anticancer treatment Methods 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (15)
1. Farmaceutski pripravak, naznačeno time, koji kao aktivni spoj sadrži inhibitorski spoj PI3K-klase I: 5-(7-metansulfonil-2-morfolin-4-il-6,7-dihidro-5H-pirolo[2,3-d]pirimidin-4-il)-pirimidin-2-amin ili njegovu farmaceutski prihvatljivu sol, za uporabu u liječenju protiv raka zajedno s drugim spojem protiv raka i pri čemu je navedeni drugi spoj protiv raka odabran iz skupine koja sadrži cetuksimab, bevacizumab, fulvestrant , ili gefitinib.
2. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačeno time, da se koristi u liječenju raka debelog crijeva, raka prostate, raka dojke, raka pluća, raka jajnika.
3. Farmaceutski pripravak u skladu s patentnim zahtjevom 2, naznačeno time, da je za uporabu u liječenju raka debelog crijeva s mutacijama PI3KCA i divljeg tipa KRAS, raka debelog crijeva s mutacijama PI3KCA i KRAS, raka pluća nemalih stanica (NSCLC) sa ili bez mutacije na PI3KCA i EGFR, HER2-pozitivni rak dojke s PI3KCA mutacijom, HER2-pozitivan i ER-pozitivan rak dojke.
4. Farmaceutski pripravak za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time, da je prikladan za oralnu primjenu inhibitora PI3k-klase I, za uporabu u kombinaciji s pripravkom koji sadrži drugi spoj protiv raka.
5. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 4, naznačeno time, da sadrži količinu inhibitora PI3K-klase 1 dovoljnu za jediničnu dozu od 1 do 10 mg/kg tjelesne težine.
6. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 5, naznačeno time, da je za jediničnu dozu inhibitora PI3K-klase 1 od 5 do 7 mg/kg tjelesne težine.
7. Farmaceutski pripravak za uporabu u skladu s bilo kojim od patentnih zahtjeva 4 do 6, naznačeno time, da se koristi zajedno s farmaceutskim pripravkom koji je prikladan za oralnu ili parenteralnu primjenu drugog spoja protiv raka.
8. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 7, naznačeno time, da se koristi zajedno s farmaceutskim pripravkom koji sadrži količinu drugog spoja protiv raka prikladnu za jediničnu dozu od 10 do 80 mg/kg tjelesne težine.
9. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 8, naznačeno time, da se koristi zajedno s farmaceutskim pripravkom koji sadrži količinu drugog spoja protiv raka prikladnu za jediničnu dozu od 20 do 70 mg/kg tjelesne težine, poželjno od 30 do 50 mg/kg tjelesna težina.
10. Komplet dijelova, naznačeno time, da sadrži farmaceutski pripravak koji kao aktivni spoj sadrži spoj inhibitor PI3K-klase I: 5-(7-metansulfonil-2-morfolin-4-il-6,7-dihidro-5H-pirolo[2, 3-d]pirimidin- 4-il)-pirimidin-2-amin ili njegovu farmaceutski prihvatljivu sol, i drugi farmaceutski pripravak koji sadrži drugi spoj protiv raka, a pri čemu je navedeni drugi spoj protiv raka odabran iz skupine koja sadrži cetuksimab, bevacizumab, fulvestrant ili gefitinib, za uporabu u kombiniranom liječenju protiv raka.
11. Komplet dijelova za uporabu u skladu s patentnim zahtjevom 10, naznačeno time, gdje je kombinirani tretman protiv raka debelog crijeva, prostate, dojke, pluća i jajnika.
12. Komplet dijelova u skladu s patentnim zahtjevom 11, naznačeno time, da je za uporabu u kombiniranom liječenju raka debelog crijeva s mutacijama PI3KCA i divljeg tipa KRAS, raka debelog crijeva s mutacijama PI3KCA i KRAS, raka pluća nemalih stanica (NSCLC) sa ili bez mutacije na PI3KCA i EGFR, HER2-pozitivan rak dojke s PI3KCA mutacijom, HER2-pozitivan i ER-pozitivan rak dojke.
13. Komplet dijelova za uporabu u skladu s bilo kojim od patentnih zahtjeva 10 do 12, naznačeno time, da prvi farmaceutski pripravak sadrži količinu inhibitora PI3K-klase 1 dovoljnu za jediničnu dozu od 1 do 10 mg/kg tjelesne težine, poželjno od 5 do 7 mg/kg tjelesne težine.
14. Komplet dijelova za uporabu u skladu s patentnim zahtjevom 13, naznačeno time, što drugi pripravak sadrži količinu drugog spoja protiv raka prikladnu za jediničnu dozu od 10 do 80 mg/kg tjelesne težine, poželjno od 20 do 70 mg/kg ili od 30 do 50 mg /kg tjelesne težine.
15. Komplet dijelova za uporabu u skladu s bilo kojim od patentnih zahtjeva 10 do 14, naznačeno time, da je prvi pripravak prikladan za oralnu primjenu inhibitora PI3k-klase I, a drugi pripravak je prikladan za oralnu ili parenteralnu primjenu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000004082A IT201800004082A1 (it) | 2018-03-29 | 2018-03-29 | Composizioni farmaceutiche antitumorali per terapia combinata |
| PCT/IB2019/052541 WO2019186451A1 (en) | 2018-03-29 | 2019-03-28 | Anticancer pharmaceutical compositions for combined therapy |
| EP19721103.0A EP3773595B1 (en) | 2018-03-29 | 2019-03-28 | Anticancer pharmaceutical compositions for combined therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231131T1 true HRP20231131T1 (hr) | 2024-01-05 |
Family
ID=62875088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231131TT HRP20231131T1 (hr) | 2018-03-29 | 2019-03-28 | Protutumorski farmaceutski pripravci za kombiniranu terapiju |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20210015826A1 (hr) |
| EP (1) | EP3773595B1 (hr) |
| JP (1) | JP7460596B2 (hr) |
| KR (1) | KR20200138294A (hr) |
| CN (1) | CN111918656B (hr) |
| AU (1) | AU2019244793A1 (hr) |
| BR (1) | BR112020019712A2 (hr) |
| CL (1) | CL2020002424A1 (hr) |
| DK (1) | DK3773595T3 (hr) |
| EA (1) | EA202092008A1 (hr) |
| ES (1) | ES2954502T3 (hr) |
| FI (1) | FI3773595T3 (hr) |
| HR (1) | HRP20231131T1 (hr) |
| HU (1) | HUE063047T2 (hr) |
| IL (1) | IL277649A (hr) |
| IT (1) | IT201800004082A1 (hr) |
| LT (1) | LT3773595T (hr) |
| MX (1) | MX2020010084A (hr) |
| PH (1) | PH12020551583A1 (hr) |
| PL (1) | PL3773595T3 (hr) |
| PT (1) | PT3773595T (hr) |
| RS (1) | RS64639B1 (hr) |
| RU (1) | RU2020131376A (hr) |
| SG (1) | SG11202009483YA (hr) |
| SI (1) | SI3773595T1 (hr) |
| TW (1) | TWI816768B (hr) |
| UA (1) | UA127288C2 (hr) |
| WO (1) | WO2019186451A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368114B (zh) * | 2020-03-10 | 2022-04-22 | 四川大学 | 一种吗啉嘧啶类化合物的抗肿瘤应用 |
| WO2024023766A1 (en) * | 2022-07-28 | 2024-02-01 | Berlin-Chemie Ag | P13k inhibitor combination therapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3042964A1 (en) * | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Egfr mutations |
| CL2009000241A1 (es) * | 2008-02-07 | 2010-09-03 | Chugai Pharmaceutical Co Ltd | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. |
| EP2616078B1 (en) * | 2010-09-16 | 2019-12-25 | Shimoda Biotech (Pty) Ltd | Fulvestrant compositions and methods of use |
| WO2012118978A1 (en) * | 2011-03-03 | 2012-09-07 | The Regents Of The University Of Colorado, A Body Corporate | Methods for treating oncovirus positive cancers |
| US20130123255A1 (en) * | 2011-11-10 | 2013-05-16 | Chugai Seiyaku Kabushiki Kaisha | Combination of a pi3k inhibitor and a mek inhibitor |
| EP2949326A4 (en) * | 2013-01-25 | 2016-06-15 | Toshiyuki Sakai | MOLECULAR FIXED COMBINATION ACTIVE FOR TUMOR THERAPY AND PREVENTION |
| PT2968294T (pt) * | 2013-03-13 | 2019-07-19 | Oncoceutics Inc | 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-hexahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona para utilização no tratamento de cancro |
| WO2014203129A1 (en) * | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
| WO2015069217A1 (en) * | 2013-11-05 | 2015-05-14 | Baylor College Of Medicine | Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis |
| WO2015095807A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of egfr and erk inhibitors |
| FR3033499A1 (fr) * | 2015-03-11 | 2016-09-16 | Centre Leon-Berard | Composition pour le traitement des tumeurs neuroendocrines pancreatiques |
| WO2016193955A1 (en) * | 2015-06-04 | 2016-12-08 | Giorgio Stassi | Combinations of kinase inhibitors for treating colorectal cancer |
-
2018
- 2018-03-29 IT IT102018000004082A patent/IT201800004082A1/it unknown
-
2019
- 2019-03-25 TW TW108110267A patent/TWI816768B/zh active
- 2019-03-28 RU RU2020131376A patent/RU2020131376A/ru unknown
- 2019-03-28 LT LTEPPCT/IB2019/052541T patent/LT3773595T/lt unknown
- 2019-03-28 KR KR1020207030500A patent/KR20200138294A/ko not_active Application Discontinuation
- 2019-03-28 CN CN201980022867.8A patent/CN111918656B/zh active Active
- 2019-03-28 EA EA202092008A patent/EA202092008A1/ru unknown
- 2019-03-28 SI SI201930630T patent/SI3773595T1/sl unknown
- 2019-03-28 MX MX2020010084A patent/MX2020010084A/es unknown
- 2019-03-28 WO PCT/IB2019/052541 patent/WO2019186451A1/en active Application Filing
- 2019-03-28 HR HRP20231131TT patent/HRP20231131T1/hr unknown
- 2019-03-28 ES ES19721103T patent/ES2954502T3/es active Active
- 2019-03-28 EP EP19721103.0A patent/EP3773595B1/en active Active
- 2019-03-28 HU HUE19721103A patent/HUE063047T2/hu unknown
- 2019-03-28 BR BR112020019712-2A patent/BR112020019712A2/pt unknown
- 2019-03-28 FI FIEP19721103.0T patent/FI3773595T3/fi active
- 2019-03-28 PL PL19721103.0T patent/PL3773595T3/pl unknown
- 2019-03-28 US US17/042,458 patent/US20210015826A1/en active Pending
- 2019-03-28 DK DK19721103.0T patent/DK3773595T3/da active
- 2019-03-28 AU AU2019244793A patent/AU2019244793A1/en active Pending
- 2019-03-28 SG SG11202009483YA patent/SG11202009483YA/en unknown
- 2019-03-28 JP JP2021501123A patent/JP7460596B2/ja active Active
- 2019-03-28 UA UAA202006896A patent/UA127288C2/uk unknown
- 2019-03-28 RS RS20230878A patent/RS64639B1/sr unknown
- 2019-03-28 PT PT197211030T patent/PT3773595T/pt unknown
-
2020
- 2020-09-21 CL CL2020002424A patent/CL2020002424A1/es unknown
- 2020-09-28 PH PH12020551583A patent/PH12020551583A1/en unknown
- 2020-09-29 IL IL277649A patent/IL277649A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IT201800004082A1 (it) | 2019-09-29 |
| FI3773595T3 (fi) | 2023-09-01 |
| MX2020010084A (es) | 2021-01-15 |
| ES2954502T3 (es) | 2023-11-22 |
| RS64639B1 (sr) | 2023-10-31 |
| CN111918656A (zh) | 2020-11-10 |
| EP3773595A1 (en) | 2021-02-17 |
| SG11202009483YA (en) | 2020-10-29 |
| PT3773595T (pt) | 2023-09-07 |
| WO2019186451A1 (en) | 2019-10-03 |
| BR112020019712A2 (pt) | 2021-02-09 |
| CL2020002424A1 (es) | 2021-03-12 |
| EA202092008A1 (ru) | 2021-01-18 |
| LT3773595T (lt) | 2023-09-25 |
| TW202002984A (zh) | 2020-01-16 |
| DK3773595T3 (da) | 2023-09-18 |
| JP7460596B2 (ja) | 2024-04-02 |
| PH12020551583A1 (en) | 2021-09-13 |
| KR20200138294A (ko) | 2020-12-09 |
| US20210015826A1 (en) | 2021-01-21 |
| PL3773595T3 (pl) | 2023-11-27 |
| JP2021519821A (ja) | 2021-08-12 |
| AU2019244793A1 (en) | 2020-10-08 |
| RU2020131376A (ru) | 2022-04-29 |
| CN111918656B (zh) | 2023-08-08 |
| TWI816768B (zh) | 2023-10-01 |
| EP3773595B1 (en) | 2023-07-12 |
| SI3773595T1 (sl) | 2023-11-30 |
| HUE063047T2 (hu) | 2023-12-28 |
| IL277649A (en) | 2020-11-30 |
| UA127288C2 (uk) | 2023-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11975002B2 (en) | Preparation and composition for treatment of malignant tumors | |
| HRP20210871T1 (hr) | Piridopirimdinonski inhibitori cdk2/4/6 | |
| JP2015532292A5 (hr) | ||
| RU2013148732A (ru) | Комбинации соединений, ингибирующих акт, и химиотерапевтических агентов и способы их применения | |
| JP2019511526A5 (hr) | ||
| HRP20161114T1 (hr) | Sastavi inhibitora kinaze i njihova uporaba za liječenje raka i drugih bolesti povezanih s kinazama | |
| SG10201804024VA (en) | Formulations of azaindole compounds | |
| MX2021001096A (es) | 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia. | |
| JP2015536986A5 (hr) | ||
| HRP20231131T1 (hr) | Protutumorski farmaceutski pripravci za kombiniranu terapiju | |
| JP2017536408A5 (hr) | ||
| ES2889573T3 (es) | Administración en múltiples bolos de [6R]-MTHF en quimioterapia basada en 5-fluorouracilo | |
| MX2010012937A (es) | Combinacion farmaceutica. | |
| HRP20191927T1 (hr) | Terapijsko liječenje | |
| JPWO2019152530A5 (hr) | ||
| TW201513870A (zh) | 含伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2016522826A5 (hr) | ||
| FI3405197T3 (fi) | Kroonisen käsi-ihottuman hoito | |
| Schöffski et al. | Tolerability and anti-tumor activity of the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer | |
| ES2703739T3 (es) | Combinación terapéutica que comprende un inhibidor aurora cinasa y un agente antineoplásico | |
| Baldi et al. | Rationale and Design of PEMVITASTART—An Open-label Randomized Trial Comparing Simultaneous Versus Standard Initiation of Vitamin B12 and Folate Supplementation in Nonsquamous, Non–Small-cell Lung Cancer Patients Undergoing First-line Pemetrexed-based Chemotherapy | |
| Rabasseda | International Association for the Study of Lung Cancer-16th World Conference on Lung Cancer. Denver, Colorado, USA-September 6-9, 2015 | |
| BR112020003585A2 (pt) | composição para uso no tratamento, prevenção ou retardamento da progressão de tumores sólidos que incluem câncer em um ser humano | |
| TW201313225A (zh) | 與放射線治療關聯之包含奧瑞布林（ｏｍｂｒａｂｕｌｉｎ）及順鉑（ｃｉｓｐｌａｔｉｎ）之抗腫瘤組合 | |
| JP2014034533A (ja) | Ｈｓｐ９０阻害剤とｅｇｆｒチロシンキナーゼ阻害剤の組み合わせ |